Vivo Capital, LLC

PALO ALTO, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$908.7M2026 Q3
Positions50
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.51.3%

Vivo Capital, LLC reported 50 positions worth $908.7M as of September 30, 2026 (13F filed November 13, 2026). Largest holding: PRAX (8.7%). Biggest move: exit SVA ($38.2M).

10 / 50 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 PRAXPraxis Precision Medicines$79.0M8.69%271,116——+6.5%
▸ 2 TRVITrevi Therapeutics$60.6M6.67%4,229,683——-7.2%
▸ 3 ERASErasca$58.9M6.49%4,020,619———
▸ 4 AVBPArriVent BioPharma$54.1M5.96%1,787,104——-57.0%
▸ 5 ABVXAbivax S.A.$41.1M4.52%414,899———
▸ 6 ENTXEntera Bio$35.7M3.92%12,254,901——+2.7%
▸ 7 ACRSAclaris Therapeutics$35.2M3.88%6,694,637——-28.9%
▸ 8 ANROAlto Neuroscience$34.7M3.82%1,359,915——+6.2%
▸ 9 TNGXTango Therapeutics$34.4M3.79%1,379,769——-3.1%
▸ 10 CRVSCorvus Pharmaceuticals$32.3M3.56%2,805,816——-8.0%

Pro Feature

The remaining 40 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Vivo Capital, LLC hold as of Q3 2026?

Vivo Capital, LLC reported 50 positions worth $908.7M in its Q3 2026 13F filing. Largest positions: PRAX (8.7%), TRVI (6.7%), ERAS (6.5%), AVBP (6.0%) and ABVX (4.5%).

What did Vivo Capital, LLC buy in Q3 2026?

New positions: ENTX, KRSA, Blossomhill Therapeutics Inc, VOR and Cue Biopharma Inc (8 in all). Added to: CAMP, ANRO, FTH, AVBP and InMed Pharmaceuticals Inc.

What did Vivo Capital, LLC sell in Q3 2026?

Reduced: DYN, ORIC, TRVI, DRUG and CMPX (8 in all). Sold out entirely: SVA, DNTH, GERN, ALXO and UNCY.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.